{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-22-056484","form_type":"8-K","ticker":"NXTC","cik":"0001661059","company_name":"NextCure, Inc.","filed_at":"2022-05-05T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.691139+00:00","generated_at":"2026-06-25T23:47:37.657841+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NextCure reports Q1 2022 net loss of $20.6M; cash at $201.3M, runway into Q1 2024","bullets":["Net loss of $20.6M vs $16.5M in Q1 2021, driven by higher R&D expenses.","Cash, cash equivalents and securities of $201.3M, down $18.3M from Dec 2021.","On track for H2 2022 milestones: NC318 Phase 2 update, NC410 Phase 1 update, NC762 initial data, NC525 IND filing.","Cash expected to fund operations into Q1 2024.","R&D expenses $15.0M (Q1 2022) vs $12.4M (Q1 2021); G&A $5.8M vs $4.9M."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-22-056484","json":"https://secwatch.observer/filing/0001104659-22-056484.json","markdown":"https://secwatch.observer/filing/0001104659-22-056484.md","text":"https://secwatch.observer/filing/0001104659-22-056484.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1661059/000110465922056484/0001104659-22-056484-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1661059/000110465922056484/tm2214609d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T23:47:37.657841+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}